Skip to main contentAI and Advanced
/
NOVELIX · BSEMarket ticker unavailable · configure an authorised index feed
NO
BSE · Equity shares · Not available-1.00 · -1.25%
NOVELIX PHARMACEUTICALS LIMITE NOVELIX
NSE:Not available
BSE:INR 79
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsData unavailable
Research sections2 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
This listed security has price history but no canonical company-fundamentals document. Financials, valuation, ownership and company-profile gaps are source coverage gaps, not zero values.
AI analysis and Advanced tools for NOVELIX
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 80
Day rangeINR 76 — INR 81.99
52-week rangeINR 66.5 — INR 83.99
Volume11,761
Market capNot available
P/ENot available
Research path: Interpret NOVELIX PHARMACEUTICALS LIMITE's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NOVELIXNOVELIX PHARMACEUTICALS LIMITE1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
Financial statement rows are unavailable.
Fundamentals
Valuation and ratios
Valuation data unavailable.
Risk and consensus
Source-qualified signals
Risk metrics
Risk metrics unavailable.
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
Ownership data is not present in the normalized source.
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Relevant company news is unavailable.
Corporate actions
Events
Corporate event data unavailable.
Rusaka Markets Community
Discussion and sentiment for NOVELIX PHARMACEUTICALS LIMITE
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Not available
Company facts
- NSE Code
- NOVELIX
Questions
Stock FAQ
What is the symbol and ISIN of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has the symbol NOVELIX and ISIN - INE314I01036.
What is the current price of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE is currently trading at INR 79.00.
What are the year high and year low of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a year high of INR 83.99 and a year low of INR 66.50.
What is the market capitalization of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a market capitalization of NA.
What is the P/E ratio of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a P/E ratio of NA.
What is the dividend yield of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a dividend yield of NA.
How is the financial performance of NOVELIX PHARMACEUTICALS LIMITE based on revenue, net income, and EPS?
NOVELIX PHARMACEUTICALS LIMITE has revenue of NA, net income of NA, and EPS of NA.
What is the book value of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a book value of NA.
What is the debt-to-equity ratio of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of NOVELIX PHARMACEUTICALS LIMITE?
NOVELIX PHARMACEUTICALS LIMITE has a price-to-book ratio of NA and a price-to-sales ratio of NA.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.